연구성과로 돌아가기

2025 연구자 정보 (22 / 657)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Sim, Ha Seon
(Sim, H) ⓘ 		Kyungpook Natl Univ, Dept Hort Sci, Daegu 41566, South Korea
Kyungpook Natl Univ, Coll Agr & Sci, Dept Hort Sci, Daegu 41566, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.6] Novel method for crop growth tracking with deep learning model on an Edge Rail Camera
[JCR상위 30.0] Development of a strawberry transpiration model based on a simplified Penman-Monteith model under different irrigation regimes ⓘ 		SCIE ⓘ 1.6 AGRICULTURE, MULTIDISCIPLINARY;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS
HORTICULTURE ⓘ 		swkum@keti.re.kr; jwmoon@keti.re.kr; stoh@keti.re.kr; davidsuh79@sejong.edu; hyunji7674@gmail.com; dlfurgml1@knu.ac.kr; jungsu@knu.ac.kr; skkim76@knu.ac.kr; nare@naretrends.com; francisco.andres@ctingenieros.es;
skkim76@knu.ac.kr; ⓘ
Suh, Hyun Kwon
(Suh, HK) ⓘ 		Sejong Univ, Dept Integrat Biol Sci & Ind, Seoul 05006, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.6] Novel method for crop growth tracking with deep learning model on an Edge Rail Camera ⓘ SCIE ⓘ 1.6 AGRICULTURE, MULTIDISCIPLINARY;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS ⓘ swkum@keti.re.kr; jwmoon@keti.re.kr; stoh@keti.re.kr; davidsuh79@sejong.edu; hyunji7674@gmail.com; dlfurgml1@knu.ac.kr; jungsu@knu.ac.kr; skkim76@knu.ac.kr; nare@naretrends.com; francisco.andres@ctingenieros.es; ⓘ
Yamaguchi, Tetsuo
(Yamaguchi, T) ⓘ 		제1저자 Dongguk Univ, Dept Energy & Mat Engn, Seoul 04620, South Korea
Kwansei Gakuin Univ, Dept Appl Chem Environm, Sanda, Hyogo 6691330, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.6] Stabilization of chemically flexible indigo dye against photodegradation under solvent condition through intercalation into layered double hydroxide ⓘ SCIE ⓘ 1.6 CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;MINERALOGY ⓘ jaemin.oh@dongguk.edu; ⓘ
Al-Ahmadie, Hikmat
(Al-Ahmadie, H) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Antonuzzo, Lorenzo
(Antonuzzo, L) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Atduev, Vagif
(Atduev, V) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Baek, John
(Baek, J) ⓘ 		BeamWorks Inc, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study.
[JCR상위 91.3] Clinical Application of Artificial Intelligence in Breast Ultrasound ⓘ 		SCIE
ESCI ⓘ 		1.7 ONCOLOGY
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING ⓘ 		greenoaktree9@gmail.com; ⓘ
Barroso-Sousa, Romualdo
(Barroso-Sousa, R) ⓘ 		ⓘ T-6405-2019
BARROSO-SOUSA, ROMUALDO ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Bin Lee, Yun
(Lee, YB) ⓘ 		Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B
[JCR상위 1.0] Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial ⓘ 		SCIE ⓘ 1.0 GASTROENTEROLOGY & HEPATOLOGY ⓘ pindra@empal.com;
limys@amc.seoul.kr; ⓘ
Cao, Ke
(Cao, K) ⓘ 		Brii Biosci Beijing Co Ltd, Beijing, Peoples R China ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ jia_jd@ccmu.edu.cn; ⓘ
Casalnuovo, Monica
(Casalnuovo, M) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Catto, James W. F.
(Catto, JWF) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Chae, Yee Soo
(Chae, YS) ⓘ 		Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea
Kyungpook Natl Univ, Sch Med, Dept Hematooncol, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study.
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
[JCR상위 1.7] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
[JCR상위 38.0] Comparative analysis of the lumboperitoneal shunt versus ventriculoperitoneal shunt for leptomeningeal metastasis-associated hydrocephalus in non-small cell lung cancer
[JCR상위 1.7] Role of EMP2 in triple-negative breast cancer.
[JCR상위 1.7] Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features. ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
CLINICAL NEUROLOGY;SURGERY ⓘ 		kiss798@gmail.com; ⓘ
Chang, Chao-Hsiang
(Chang, CH) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Chaudhari, Mukesh
(Chaudhari, M) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
페이지 이동: